iCAD (NASDAQ:ICAD) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a research note issued to investors on Thursday morning.

iCAD Price Performance

Shares of ICAD stock opened at $1.54 on Thursday. The firm has a market capitalization of $40.87 million, a price-to-earnings ratio of -11.85 and a beta of 1.47. iCAD has a 12-month low of $1.18 and a 12-month high of $2.65. The firm has a fifty day moving average of $1.72 and a 200-day moving average of $1.54.

Hedge Funds Weigh In On iCAD

Several institutional investors and hedge funds have recently modified their holdings of the business. Essex LLC bought a new position in iCAD in the third quarter valued at approximately $216,000. Perritt Capital Management Inc boosted its stake in iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after purchasing an additional 19,917 shares during the period. Virtu Financial LLC increased its holdings in iCAD by 55.6% during the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock worth $34,000 after purchasing an additional 7,604 shares in the last quarter. Finally, Perritt Capital Management Inc. raised its stake in shares of iCAD by 7.5% in the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after purchasing an additional 9,717 shares during the period. 24.61% of the stock is currently owned by institutional investors and hedge funds.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.